POZEN welcomes Dr Seth Rudnick on board
This article was originally published in Scrip
POZEN has elected Dr Seth Rudnick, a venture partner at Canaan Partners and clinical adjunct professor of medicine at the University of North Carolina, Chapel Hill, to its board of directors. Dr Rudnick has led many drug discovery and development projects throughout his career, which spans R&D, clinical trials analysis and biotechnology. He was previously CEO and chairman of Cyto Therapeutics, and has also worked for the Ortho Biotech division of Johnson & Johnson.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.